The Centers for Medicare and Medicaid Services (CMS) has added 15 drugs, including Trulicity and Biktarvy, to its price negotiation program, a move that could impact Eli Lilly (LLY) and Gilead Sciences (GILD). The new prices are scheduled to take effect starting in 2028.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments